GLASSIA
471501
Phase 3 mab terminated
Quick answer
GLASSIA for Graft Versus Host Disease is a Phase 3 program (mab) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda Pharmaceuticals International AG
- Indication
- Graft Versus Host Disease
- Phase
- Phase 3
- Modality
- mab
- Status
- terminated